BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 31558699)

  • 1. SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA/FAK signaling pathway regulation.
    Zeng Y; Cao Y; Liu L; Zhao J; Zhang T; Xiao L; Jia M; Tian Q; Yu H; Chen S; Cai Y
    Cell Death Dis; 2019 Sep; 10(10):720. PubMed ID: 31558699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Septin 9_i2 is downregulated in tumors, impairs cancer cell migration and alters subnuclear actin filaments.
    Verdier-Pinard P; Salaun D; Bouguenina H; Shimada S; Pophillat M; Audebert S; Agavnian E; Coslet S; Charafe-Jauffret E; Tachibana T; Badache A
    Sci Rep; 2017 Mar; 7():44976. PubMed ID: 28338090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway.
    Amir S; Golan M; Mabjeesh NJ
    Mol Cancer Res; 2010 May; 8(5):643-52. PubMed ID: 20407014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The concerted action of SEPT9 and EPLIN modulates the adhesion and migration of human fibroblasts.
    Hecht M; Alber N; Marhoffer P; Johnsson N; Gronemeyer T
    Life Sci Alliance; 2024 Jul; 7(7):. PubMed ID: 38719752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Septin 9 isoforms promote tumorigenesis in mammary epithelial cells by increasing migration and ECM degradation through metalloproteinase secretion at focal adhesions.
    Marcus J; Bejerano-Sagie M; Patterson N; Bagchi S; Verkhusha VV; Connolly D; Goldberg GL; Golden A; Sharma VP; Condeelis J; Montagna C
    Oncogene; 2019 Jul; 38(30):5839-5859. PubMed ID: 31285548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardin-related transcription factor A (MRTF-A) activity-dependent cell adhesion is correlated to focal adhesion kinase (FAK) activity.
    Kishi T; Mayanagi T; Iwabuchi S; Akasaka T; Sobue K
    Oncotarget; 2016 Nov; 7(44):72113-72130. PubMed ID: 27708220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression.
    Connolly D; Yang Z; Castaldi M; Simmons N; Oktay MH; Coniglio S; Fazzari MJ; Verdier-Pinard P; Montagna C
    Breast Cancer Res; 2011 Aug; 13(4):R76. PubMed ID: 21831286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic profiling of the oncogenic septin 9 reveals isoform-specific interactions in breast cancer cells.
    Devlin L; Okletey J; Perkins G; Bowen JR; Nakos K; Montagna C; Spiliotis ET
    Proteomics; 2021 Oct; 21(19):e2100155. PubMed ID: 34409731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARHGAP4-SEPT2-SEPT9 complex enables both up- and down-modulation of integrin-mediated focal adhesions, cell migration, and invasion.
    Kang N; Matsui TS; Liu S; Deguchi S
    Mol Biol Cell; 2021 Nov; 32(21):ar28. PubMed ID: 34524873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Septin11 promotes hepatocellular carcinoma cell motility by activating RhoA to regulate cytoskeleton and cell adhesion.
    Fu L; Wang X; Yang Y; Chen M; Kuerban A; Liu H; Dong Y; Cai Q; Ma M; Wu X
    Cell Death Dis; 2023 Apr; 14(4):280. PubMed ID: 37080972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AmotP130 regulates Rho GTPase and decreases breast cancer cell mobility.
    Chen ZL; Yang J; Shen YW; Li ST; Wang X; Lv M; Wang BY; Li P; Zhao W; Qiu RY; Liu Y; Liu PJ; Yang J
    J Cell Mol Med; 2018 Apr; 22(4):2390-2403. PubMed ID: 29377471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of caveolin-1 in low shear stress-induced breast cancer cell motility and adhesion: Roles of FAK/Src and ROCK/p-MLC pathways.
    Xiong N; Li S; Tang K; Bai H; Peng Y; Yang H; Wu C; Liu Y
    Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):12-22. PubMed ID: 27773611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forchlorfenuron disrupts SEPT9_i1 filaments and inhibits HIF-1.
    Vardi-Oknin D; Golan M; Mabjeesh NJ
    PLoS One; 2013; 8(8):e73179. PubMed ID: 23977378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enterolactone alters FAK-Src signaling and suppresses migration and invasion of lung cancer cell lines.
    Chikara S; Lindsey K; Borowicz P; Christofidou-Solomidou M; Reindl KM
    BMC Complement Altern Med; 2017 Jan; 17(1):30. PubMed ID: 28068967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Septin 9 isoform 1 (SEPT9_i1) specifically interacts with importin-α7 to drive hypoxia-inducible factor (HIF)-1α nuclear translocation.
    Tazat K; Schindler S; Depping R; Mabjeesh NJ
    Cytoskeleton (Hoboken); 2019 Jan; 76(1):123-130. PubMed ID: 29742803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells.
    Gilkes DM; Xiang L; Lee SJ; Chaturvedi P; Hubbi ME; Wirtz D; Semenza GL
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):E384-93. PubMed ID: 24324133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SEPT9_i1 is required for the association between HIF-1α and importin-α to promote efficient nuclear translocation.
    Golan M; Mabjeesh NJ
    Cell Cycle; 2013 Jul; 12(14):2297-308. PubMed ID: 24067372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysophosphatidic acid induces a migratory phenotype through a crosstalk between RhoA-Rock and Src-FAK signalling in colon cancer cells.
    Leve F; Marcondes TG; Bastos LG; Rabello SV; Tanaka MN; Morgado-Díaz JA
    Eur J Pharmacol; 2011 Dec; 671(1-3):7-17. PubMed ID: 21968138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paxillin, a novel controller in the signaling of estrogen to FAK/N-WASP/Arp2/3 complex in breast cancer cells.
    Shortrede JE; Uzair ID; Neira FJ; Flamini MI; Sanchez AM
    Mol Cell Endocrinol; 2016 Jul; 430():56-67. PubMed ID: 27095481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIEN1 drives breast tumor cell migration by regulating cytoskeletal-focal adhesion dynamics.
    Kpetemey M; Chaudhary P; Van Treuren T; Vishwanatha JK
    Oncotarget; 2016 Aug; 7(34):54913-54924. PubMed ID: 27462783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.